CHI3L1 and metastatic malignant neoplasm: It has been reported that 16–74% of patients had elevated levels of serum YKL40 at the time of first cancer diagnosis; however, the percentage increased from 39–83% at diagnosis in patients with metastatic cancer (Johansen et al. 2006).